The final week of September brought a sobering statistic that demands attention from anyone responsible for workplace safety: ketamine-related deaths have increased twenty-fold since 2014. But as King’s College London researchers point out, the story isn’t quite that simple—and the implications for drug testing programmes are significant.
The Ketamine Crisis: Not Just About Ketamine
Research from King’s College London reveals that whilst ketamine deaths have surged dramatically, these fatalities increasingly occur in complex polydrug settings. This raises a critical question for employers: are single-substance testing policies still fit for purpose?
The findings suggest that traditional drug testing approaches—checking for individual substances in isolation—may miss the bigger picture of how employees actually use drugs. When someone tests positive for ketamine, they’re likely using other substances too, creating unpredictable impairment risks that standard testing might not fully capture.
For UK employers, particularly in safety-critical industries, this means reassessing testing panels. A Lancashire mother’s story this week provided a stark human illustration: her ketamine addiction left her requiring a new bladder, with irreversible damage that no amount of treatment could repair. The physical toll extends well beyond immediate impairment.
Scotland’s Drug Treatment Data: Mixed Messages
Public Health Scotland released several datasets this week that paint a complex picture of substance use north of the border. Drug and alcohol treatment waiting times showed 10,641 referrals between April and June, with alcohol accounting for 48.1%, drugs for 37.5%, and co-dependency for 14.4%.
Meanwhile, opioid substitution therapy reached an estimated 28,015 people in the year to March 2025—down slightly from 28,644 the previous quarter. For employers, these figures indicate ongoing challenges with opiates and prescription drugs that can impair workplace performance and safety.
The Scottish government also faced questions in Parliament about alcohol-specific deaths remaining above 1,000 for the twelfth consecutive year, with those in the most deprived communities four and a half times more likely to die from alcohol-related causes than those in the least deprived areas.
Northern Ireland’s Alcohol Burden Quantified
A new report from the Sheffield Addictions Research Group commissioned by British Heart Foundation Northern Ireland provides hard numbers on alcohol’s impact on healthcare systems. Whilst the report focuses on hospital admissions and deaths, the workplace implications are clear: alcohol remains a significant occupational health challenge that many employers still underestimate.
The report’s timing coincided with a Northern Ireland Assembly debate on drug-testing schemes at festivals and concerts, with calls to learn from Ireland’s Health Service Executive rapid drug-checking programmes at events like Electric Picnic. The harm reduction discussion continues to evolve, though workplace testing remains firmly focused on fitness for duty rather than harm reduction.
Vaping, Smoking and the Stoptober Push
October marked the return of Stoptober 2025, with the Department of Health and Social Care rolling out resources to encourage quit attempts. NHS Highland revealed that smoking costs its health board up to £30 million annually, prompting a five-year tobacco and vaping strategy as youth vaping rates climb.
The debate around vaping regulation intensified, with three shops in Newmarket, Suffolk closed for selling illegal vapes and tobacco, and Ireland confirming its delayed vape tax will take effect from 1 November. For employers, the challenge remains distinguishing between smoking cessation tools and new nicotine dependencies that could affect workplace performance.
International Developments with UK Relevance
Across the Atlantic, research continues highlighting gender differences in substance use. A West Virginia University study suggested that men’s tendency to combine alcohol with fentanyl and other drugs partly explains higher male overdose deaths—a pattern worth considering when designing workplace drug policies.
Meanwhile, a JAMA Network Open study of 375 primary care professionals in Ohio found they were more willing to treat type 2 diabetes than opioid use disorder, despite viewing diabetes as more complicated and having more empathy toward patients with OUD. The stigma around addiction clearly extends into healthcare settings, let alone workplaces.
Australia’s New South Wales saw its Supreme Court rule that police suspicion of drug possession alone isn’t sufficient grounds for strip-searches—a reminder that drug policy continues evolving globally, even as workplace testing remains focused on safety rather than law enforcement.
What This Week Means for Employers
The ketamine polydrug findings should prompt employers to review their testing panels. Are you testing for the right substances? Single-drug positives may tell only part of the story when employees combine multiple substances.
The Scottish data underscores that alcohol and opiates remain persistent workplace challenges despite years of awareness campaigns. Random testing programmes and clear fitness-for-duty policies remain essential, particularly in safety-critical roles.
The vaping regulatory landscape continues shifting, but the workplace question remains straightforward: does substance use—whether traditional smoking, vaping, or other drugs—affect an employee’s ability to perform their role safely?
Testing Solutions for Complex Challenges
At ZoomTesting, we understand that modern drug use patterns require sophisticated detection approaches. Whether you need comprehensive multi-panel urine drug tests for pre-employment screening or rapid saliva drug tests for reasonable suspicion testing, we provide reliable, legally defensible testing solutions.
Our expert team stays current with evolving substance use trends to ensure your testing programme remains effective. Contact us today to discuss how we can support your workplace drug testing requirements with accurate, affordable solutions backed by over a decade of UK drug testing expertise.
Photo by Anthony Cunningham for Zoom Testing
